ST HULUWA: Obtained Drug Registration Certificate

HULUWA announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Metformin and Ertugliflozin Tablets and Inhalation Compound Ipratropium Bromide Solution. Among them, the research and development expenses for Metformin and Ertugliflozin Tablets have totaled 11.6007 million yuan, and the research and development expenses for Inhalation Compound Ipratropium Bromide Solution have totaled 3.1696 million yuan